Targeting Sigma-1 Receptor (σ1R) with Fluorescent Ligands: Advancing Assay Design in CNS Drug Discovery

Understanding the intricate mechanisms of central nervous system (CNS) disorders requires precise tools to study key molecular players. Among these, sigma-1 receptor (σ₁R) has emerged as a significant modulator of neuronal function, implicated in neuroprotection, neuroplasticity, and neuroinflammation. Exploring the unique properties of this receptor in central nervous system (CNS) pathophysiology has opened new avenues for therapeutic intervention in disorders ranging from depression to neurodegenerative diseases. The development of fluorescent ligands tailored to this receptor allows the visualization of receptor interactions with cellular components in real-time, tracking receptor movements, and identifying potential drug targets in the CNS field. This approach provides a non-radioactive method for studying σ₁R binding and function, offering an alternative to traditional radioligand binding assays.

Sigma-1 Receptor: Structure, Function, and Role in CNS Disorders

Unlike classic G protein–coupled receptors (GPCRs), the sigma-1 receptor is a non-opioid, chaperone-like protein residing primarily in the mitochondrial-associated endoplasmic reticulum membrane (MAM). Its structure, first resolved by cryo-EM in recent years, reveals a trimeric architecture with a single transmembrane domain and a ligand-binding cavity, capable of interacting with diverse small molecules. Understanding sigma-1 receptor structure has opened new avenues for the rational design of ligands and assay systems.

Contrary to classical receptors, it modulates multiple signaling pathways through protein-protein interactions rather than direct signal transduction. This regulatory role is implicated in multiple CNS conditions. For instance, studies have shown its involvement in inflammation, neuroprotection, and synaptic remodeling, suggesting therapeutic opportunities in diseases such as Alzheimer’s, Amyotrophic Lateral Sclerosis (ALS), depression, and chronic pain. Key roles  of sigma-1 receptor include: 

• Regulation of calcium signaling and ion channels critical for neuronal excitability.
• Modulation of neuroinflammation impacting the progression of neurodegenerative diseases.
• Enhancement of neuroplasticity and synaptic function, relevant for antidepressant effects.

Advantages of Fluorescent Ligands in Sigma-1 Receptor Assays

To efficiently evaluate sigma-1 receptor pharmacology, robust ligand binding assay platforms that provide high sensitivity, real-time analysis, and scalability are required. Fluorescent ligands offer several advantages over radioligands or enzymatic readouts, especially in terms of safety, multiplexing capacity, and compatibility with high-content screening. They allow for:

• Non-radioactive detection with high signal-to-noise ratio
  
• Real-time kinetic monitoring of ligand-receptor interactions
  
• Miniaturization for high-throughput screening in 96- or 384-well formats
  
• Compatibility with confocal imaging for localization studies

Recent advances in fluorescent probe design have produced high-affinity, red-emitting ligands with strong selectivity for sigma receptors (σ₁ and σ₂). Optimized chemical scaffolds and fluorophores like near-infrared dyes enable nanomolar affinities and enhanced photophysical properties. These probes are suited for flow cytometry, confocal, and live-cell imaging, allowing reliable quantification of ligand-receptor interactions in living cells. They can effectively replace radioligand methods, supporting both real-time and endpoint assays essential for CNS drug screening.

Figure 1. Labeling of human retinal pigment epithelia (ARPE19) cells with a novel fluorescent ligand. Signal is localized to intracellular membranes. Lower intensity of labeling is detected when cells were prelabeled with the pharmacophore PB190, 100 μM. Scale bar = 20 μm. Source: Abatematteo FS, Majellaro M, et al. Development of Fluorescent 4-[4-(3H-Spiro[isobenzofuran-1,4′-piperidin]-1′-yl)butyl]indolyl Derivatives as High-Affinity Probes to Enable the Study of σ Receptors via Fluorescence-Based Techniques. J Med Chem. 2023 Mar 23;66(6):3798-3817

Designing Selective Assays: Targeting Sigma-1 Receptor in CNS Drug Discovery

Designing selective and reliable assays is essential for unraveling the pharmacological nuances of σ₁R and for accelerating CNS therapeutic discovery. Key considerations include:

• Ligand specificity

Utilizing fluorescent ligands with validated high affinity and selectivity for sigma-1 receptor avoids cross-reactivity with σ₂R or other receptor families like N-methyl-D-aspartate (NMDA) or opioid receptors.

• Optimized assay conditions

Buffer composition, incubation times, and temperature must be finely tuned to preserve receptor integrity and ligand fluorescence.

• Labeling strategies

Selecting appropriate fluorophores with favorable excitation/emission profiles and photostability enhances signal-to-noise ratios.

• Kinetic profiling

Complementary techniques such as fluorescence anisotropy or Förster resonance energy transfer (FRET) can elucidate binding kinetics and receptor conformational states.

The development of tailored assays is often supported by structure-guided probe design and the use of advanced linker chemistries that preserve both target affinity and fluorescence integrity. While the resulting tools vary in complexity, they must maintain consistent performance across multiple platforms (fluorimetry, flow cytometry, imaging) without introducing artifacts due to probe instability or non-specific binding.

Exploring Sigma-1 Receptor Ligands: Agonists, Antagonists, and Binding Strategies

The growing therapeutic interest in sigma receptor ligands has led to an expanded chemical landscape, ranging from synthetic compounds to repurposed CNS drugs. Depending on the intended application, the pharmacological profile of the ligand (agonist or antagonist) can have drastically different effects:

• Sigma-1 receptor agonists activate the receptor, triggering downstream effects like neuroprotection and antidepressant effects by modulating receptor functions involved in neuronal survival and plasticity. Some well-known examples of σ₁R antagonist drugs include fluvoxamine, dextromethorphan, and cutamesine (SA4503), each exhibiting neuroprotective or antidepressant effects.
  
• Sigma-1 receptor antagonists block receptor activity and are explored for mitigating drug abuse or certain neurodegenerative symptoms. Representative antagonists include haloperidol, NE-100, BD1047, and progesterone. These compounds inhibit σ1R functions and are valuable tools for dissecting receptor roles in pathology as well as potential therapeutic agents.

Binding strategies often exploit the receptor’s chaperone-like functions, with ligands designed to modulate protein interactions or stabilize specific conformations. These approaches target the receptor’s orthosteric site to achieve high affinity and selectivity, utilize allosteric binding to fine-tune receptor activity, or influence receptor trafficking and protein-protein interactions. Fluorescent ligands help visualize receptor distribution and binding dynamics in live-cell or membrane preparations, enhancing understanding of drug-receptor interactions fundamental to CNS drug development.

The successful design of σ₁R assays depends on the availability of selective, stable, and well-characterized molecular probes. At Celtarys, we enable this process by developing advanced fluorescent ligands tailored for your research. Collaborating with a partner who understands the complexity of receptor pharmacology and provides assay support is pivotal in advancing targeting sigma receptor approaches, driving discoveries that may translate into transformative CNS drugs. 

Reach out today to elevate your CNS drug discovery efforts with cutting-edge fluorescent tools and expert guidance!

References

Abatematteo FS, Majellaro M, Montsch B, Prieto-Díaz R, Niso M, Contino M, Stefanachi A, Riganti C, Mangiatordi GF, Delre P, Heffeter P, Sotelo E, Abate C. Development of Fluorescent 4-[4-(3H-Spiro[isobenzofuran-1,4′-piperidin]-1′-yl)butyl]indolyl Derivatives as High-Affinity Probes to Enable the Study of σ Receptors via Fluorescence-Based Techniques. J Med Chem. 2023 Mar 23;66(6):3798-3817. doi: 10.1021/acs.jmedchem.2c01227

Ryskamp DA, Korban S, Zhemkov V, Kraskovskaya N, Bezprozvanny I. Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases. Front Neurosci. 2019 Aug 28;13:862. doi: 10.3389/fnins.2019.00862

Wu NH, Ye Y, Wan BB, Yu YD, Liu C, Chen QJ. Emerging Benefits: Pathophysiological Functions and Target Drugs of the Sigma-1 Receptor in Neurodegenerative Diseases. Mol Neurobiol. 2021 Nov;58(11):5649-5666. doi: 10.1007/s12035-021-02524-5

Malar DS, Thitilertdecha P, Ruckvongacheep KS, Brimson S, Tencomnao T, Brimson JM. Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders. CNS Drugs. 2023 May;37(5):399-440. doi: 10.1007/s40263-023-01007-6

Piechal A, Jakimiuk A, Mirowska-Guzel D. Sigma receptors and neurological disorders. Pharmacol Rep. 2021 Dec;73(6):1582-1594. doi: 10.1007/s43440-021-00310-7